| http://www.w3.org/ns/prov#value | - WASHINGTON -- Some of the world's largest drugmakers will face an uphill battle next week in their bid to revive a class of experimental pain drugs that have been sidelined by safety concerns for nearly two years.The Food and Drug Administration says there is a clear association between the nerve-blocking medications and reports of joint failure and bone deterioration that led the agency to halt s
|
